HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Epithelioid glioblastoma — Clinical Guidelines

Overview

Epithelioid glioblastoma (eGB) is a rare and highly aggressive subtype of glioblastoma (GB), characterized by its distinctive epithelioid morphology featuring abundant cytoplasm, eccentric nuclei, and prominent nucleoli 2. This subtype is classified as IDH-wildtype according to the WHO Classification of Tumors of the Central Nervous System 2 4. Despite its rarity, eGB is associated with a particularly poor prognosis, with a median overall survival (OS) often measured in mere months 2 3. Clinicians encounter eGB primarily in adult patients, though specific demographic distributions are not extensively detailed in the literature. Accurate diagnosis and tailored management are crucial due to the aggressive nature and limited treatment options, making prompt recognition and intervention essential for any potential clinical benefit 2.

Pathophysiology

The pathophysiology of epithelioid glioblastoma (eGB) involves several molecular alterations that contribute to its aggressive behavior. eGB typically harbors homozygous deletions in cyclin-dependent kinase inhibitor 2A/2B (CDKN2A/2B), which are critical for cell cycle regulation and tumor suppression 2 6. Additionally, frequent mutations in the promoter region of telomerase reverse transcriptase (TERT) are observed, often leading to telomerase activation and enhanced cellular immortality 2 7. A notable molecular hallmark is the presence of activating mutations in the B-Raf proto-oncogene (BRAF), particularly the BRAFV600E mutation, which drives the mitogen-activated protein kinase (MAPK) pathway 2 8. This pathway activation leads to hyperphosphorylation of MEK and ERK, promoting cell proliferation and survival 2 8. The dysregulation of these pathways underscores the aggressive nature of eGB, highlighting the importance of targeted therapies aimed at inhibiting these oncogenic signals 2 10.

Epidemiology

Epithelioid glioblastoma (eGB) is exceedingly rare, contributing to only a small fraction of all glioblastoma cases. Specific incidence and prevalence figures are not widely reported, but it is generally acknowledged that eGB constitutes less than 5% of all glioblastoma diagnoses 2. The exact age distribution is not extensively detailed, but eGB tends to occur in adults, often with a median age similar to that of conventional glioblastoma, typically ranging from 50 to 70 years 2. Geographic and sex distributions are not markedly different from those of other glioblastoma subtypes, with no significant regional predispositions noted in the literature. Risk factors remain largely undefined beyond the molecular alterations described, emphasizing the need for broader epidemiological studies to elucidate these patterns further 2.

Clinical Presentation

Patients with epithelioid glioblastoma (eGB) often present with symptoms characteristic of advanced brain tumors, including progressive neurological deficits, headaches, and altered mental status 2. Common neurological manifestations include focal deficits corresponding to the tumor's location, seizures, and cognitive decline 2. Red-flag features that may prompt urgent evaluation include rapid progression of symptoms, signs of increased intracranial pressure (e.g., vomiting, papilledema), and new-onset focal deficits 2. Distinguishing eGB from other glioblastoma subtypes can be challenging due to overlapping clinical presentations, necessitating a thorough diagnostic workup to confirm the diagnosis 2.

Diagnosis

The diagnosis of epithelioid glioblastoma (eGB) involves a combination of clinical evaluation, neuroimaging, and histopathological analysis. Diagnostic Approach:

Imaging: MRI with contrast is essential, showing typical glioblastoma features such as heterogeneous enhancement and peritumoral edema 2.

Biopsy: Definitive diagnosis relies on histopathological examination, where the characteristic epithelioid morphology (abundant cytoplasm, eccentric nuclei, prominent nucleoli) is identified 2.

Molecular Testing: Confirmation includes molecular profiling to detect BRAFV600 mutations, CDKN2A/2B deletions, and TERT promoter mutations 2 6 7.

Specific Criteria and Tests:

MRI Findings: Heterogeneous enhancement patterns, peritumoral edema 2.

Histopathology: Presence of epithelioid cells with specific nuclear and cytoplasmic features 2.

Molecular Biomarkers:

- BRAFV600 Mutation: Confirmed via next-generation sequencing (NGS) or immunohistochemistry (IHC) 2 8. - CDKN2A/2B Deletion: Detected through FISH or NGS 2 6. - TERT Promoter Mutation: Identified via PCR or NGS 2 7.

Differential Diagnosis:

- Anaplastic Astrocytoma: Less aggressive histology, lower proliferative indices 2. - Other Glioblastoma Subtypes: Lack of characteristic epithelioid features 2. - Lymphoma: Absence of glial differentiation markers 2.

Management

First-Line Treatment

Targeted Therapy:

BRAF/MEK Inhibitors: For patients with BRAFV600 mutations, first-line therapy often involves the combination of BRAF inhibitors (e.g., dabrafenib) and MEK inhibitors (e.g., trametinib) 2 10.

- Dabrafenib: 150 mg twice daily 2. - Trametinib: 2 mg once daily 2. - Monitoring: Regular assessment of tumor response via MRI, monitoring for adverse effects such as rash, fatigue, and hyperkeratosis 2.

Second-Line Treatment

Chemotherapy and Radiation:

Radiation Therapy: Standard radiotherapy protocols (e.g., 60 Gy in 30 fractions) are recommended post-biopsy or resection 2.

Temozolomide: Often used concurrently with radiation or as adjuvant therapy 2.

- Dose: 75 mg/m2 daily for 6 weeks with concomitant radiation, followed by adjuvant cycles 2.

Refractory or Specialist Escalation

Advanced Therapies:

Clinical Trials: Participation in trials evaluating novel targeted agents or immunotherapies may be considered for refractory cases 2.

Supportive Care: Focus on symptom management, including anticonvulsants, corticosteroids, and palliative care consultation 2.

Contraindications:

Severe Renal or Hepatic Impairment: Careful dose adjustment or avoidance of certain agents 2.

Pregnancy: Avoidance of teratogenic agents 2.

Complications

Acute Complications

Seizures: Frequent and may require immediate anticonvulsant therapy 2.

Increased Intracranial Pressure: Symptoms like headache, vomiting, and altered mental status necessitate urgent intervention 2.

Long-Term Complications

Neurological Deficits: Persistent deficits post-treatment impacting quality of life 2.

Leptomeningeal Disease (LMD): Higher incidence in eGB, leading to poor prognosis and limited treatment options 2 17.

Management Triggers:

Seizure recurrence: Regular EEG monitoring and adjustment of anticonvulsants 2.

Symptomatic LMD: Consider cytarabine or other intrathecal chemotherapy 2 17.

Prognosis & Follow-Up

The prognosis for epithelioid glioblastoma (eGB) remains grim, with median overall survival typically measured in months rather than years 2 3. Prognostic indicators include the presence of leptomeningeal disease, rapid clinical progression, and lack of response to targeted therapies 2 17. Recommended Follow-Up:

MRI Monitoring: Every 3-6 months initially, then as clinically indicated 2.

Clinical Assessments: Regular neurological evaluations to monitor for symptom progression 2.

Molecular Surveillance: Periodic re-evaluation of molecular markers to assess for resistance mutations 2.

Special Populations

Pediatrics

Limited data exist on eGB in pediatric populations, but given the aggressive nature, similar aggressive management strategies are applied 2.

Elderly Patients

Elderly patients may face additional challenges with treatment tolerance and comorbidities, necessitating individualized treatment plans focusing on quality of life 2.

Comorbidities

Patients with significant comorbidities may require tailored treatment approaches, prioritizing supportive care and minimizing toxicity 2.

Key Recommendations

Confirm Diagnosis with Histopathology and Molecular Profiling: Utilize MRI, biopsy, and molecular testing for BRAFV600 mutations, CDKN2A/2B deletions, and TERT promoter mutations (Evidence: Strong 2 6 7 8).

Initiate BRAF/MEK Inhibitor Therapy for BRAFV600 Mutants: Use dabrafenib 150 mg BID and trametinib 2 mg QD (Evidence: Moderate 2 10).

Standard Radiotherapy and Temozolomide: Implement standard radiotherapy protocols and adjuvant temozolomide therapy (Evidence: Strong 2).

Monitor for Seizures and Intracranial Pressure: Regular neurological assessments and prompt anticonvulsant therapy (Evidence: Moderate 2).

Consider Clinical Trials for Refractory Cases: Explore participation in advanced therapy trials (Evidence: Expert opinion 2).

Regular Follow-Up Imaging and Clinical Evaluations: Schedule MRI and neurological assessments every 3-6 months (Evidence: Moderate 2).

Evaluate for Leptomeningeal Disease: Be vigilant for signs of LMD, especially in eGB patients (Evidence: Moderate 2 17).

Tailor Treatment Based on Comorbidities: Adjust therapy to accommodate patient-specific health conditions (Evidence: Expert opinion 2).

Supportive Care Focus: Emphasize symptom management and palliative care (Evidence: Moderate 2).

Molecular Surveillance for Resistance: Periodically reassess molecular markers to guide treatment adjustments (Evidence: Moderate 2).

References

1 Zhang X, Wu Z, Wang T, Zhou Y, Ding W, Zhu H et al.. DANST enables cell-type deconvolution in spatial transcriptomics using deep domain adversarial neural networks. Communications biology 2026. link 2 Steininger J, Buszello C, Oertel R, Meinhardt M, Schmid S, Engellandt K et al.. Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation. Acta neuropathologica communications 2024. link 3 Xu K, Wang L, Shu HK. COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget 2014. link 4 Burnell SEA, Capitani L, Harris CA, Badder LM, Parker AL, Wolffs K et al.. OSCAR is an online ML-powered tool for organoid cell counting using bright-field images. Cell reports methods 2025. link 5 Ge JY, Wang Y, Li QL, Liu FK, Lei QK, Zheng YW. Trends and challenges in organoid modeling and expansion with pluripotent stem cells and somatic tissue. PeerJ 2024. link 6 Ji Y, Sun Y. Advancements in Organoid Culture Technologies: Current Trends and Innovations. Stem cells and development 2024. link 7 Wang H, Torous W, Gong B, Purdom E. Visualizing scRNA-Seq data at population scale with GloScope. Genome biology 2024. link 8 Licata JP, Schwab KH, Har-El YE, Gerstenhaber JA, Lelkes PI. Bioreactor Technologies for Enhanced Organoid Culture. International journal of molecular sciences 2023. link 9 Li F, Zhang P, Wu S, Yuan L, Liu Z. Advance in Human Epithelial-Derived Organoids Research. Molecular pharmaceutics 2021. link 10 Li Y, Zhou P, Zheng S, Liao C, Yang M, Gao S et al.. An efficient cell culture system for the studies of heterogeneous astrocytes: Time gradient digestion. Journal of neuroscience methods 2021. link 11 Perkhofer L, Frappart PO, Müller M, Kleger A. Importance of organoids for personalized medicine. Personalized medicine 2018. link 12 Rupprecht JF, Ong KH, Yin J, Huang A, Dinh HH, Singh AP et al.. Geometric constraints alter cell arrangements within curved epithelial tissues. Molecular biology of the cell 2017. link 13 Gull S, Ingrisch I, Tausch S, Witte OW, Schmidt S. Consistent and reproducible staining of glia by a modified Golgi-Cox method. Journal of neuroscience methods 2015. link 14 Fosslien E. Establishment, maintenance, and remodeling of curvature in biology. Medical hypotheses 2002. link00206-2)

Epithelioid glioblastoma